London-based drugmaker GSK has announced the UK approval of Nucala (mepolizumab) as an add-on maintenance biologic treatment ...

Shares of US immunology focused biotech Zenas BioPharma tumbled more than 50% to $17.08 pre-market today despite announcing ...

Taiwanese drugmaker ScinoPharm (TWSE: 1789) has secured approval from the US Food and Drug Administration for its glatiramer ...

Chinese RNA drug developer Ribo has launched a Hong Kong IPO, positioning its lead siRNA candidate for thrombotic diseases as ...

Wegovy (semaglutide) pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 ...

New York-based clinical-stage cancer and rare diseases drug developer Protara Therapeutics today announced that the US Food ...

China-based Insilico Medicine, an AI-driven drug discovery firm, announced a multi-year research and development (R&D) ...

Suzhou-based Otovia Therapeutics has raised close to 100 million yuan ($14 million) in a new financing round, with support ...

Paul Burden (pictured, above) has been appointed associate vice president and country head of Accord UK, effective ...

French pharma Sanofi (Euronext: SAN) has won US priority review for Tzield (teplizumab-mzwv), aiming to extend use to ...

Abingworth, a transatlantic life sciences investment firm and part of global investment firm Carlyle, today announced several ...

San Diego, USA-based ARS Pharmaceuticals has announced that China’s National Medical Products Administration (NMPA) has ...